New target and treatment for Parkinson

Sharon Ronit, HUJI, School of Medicine - IMRIC, Biochemistry and Molecular Biology

New pathway to reduce toxicity of α-Synuclein


Parkinson’s disease, α-Synuclein, Brain lipids

Development Stage

Proof of concept demonstrated

Patent Status

Provisional patent application filed


Parkinson’s Disease is a neurodegenerative disorder affecting over four million people worldwide. The market for Parkinson's disease drugs predicted to reach $3.7 billion in 2015.


  • The protein α-Synuclein (α-Syn ) is a neuronal protein that is critically implicated in the pathogenesis of Parkinson’s and other neurodegenerative diseases, including Alzheimer’s disease.
  • α-Syn interacts with brain lipids.
  • New pathways involved in the pathogenicity of α-Syn have been discovered.
  • There is a pressing need for treatments that will both manage the symptoms of the disease and also slow its progression, while reducing incapacitating side effects.
  • These will lead to more focused and effective treatments for Parkinson’s.

Our Innovation

New approach to treating Parkinson’s disease uses agonists/antagonists of specific nuclear receptors to inhibit α-Syn cytotoxicity and pathogenicity. In addition, specific compounds that interfere with the metabolism of phospholipids are employed to inhibit α -Syn cytotoxicity and pathogenicity

Key Features

  • More closely focused on causes of Parkinson’s disease
  • Treats the disease rather than the symptoms

Development Milestones

Seeking industrial cooperation for further development

The Opportunity

Parkinson’s disease and the related synucleinopathies, including familial and sporadic forms of the disease, involving α-Syn–related toxicity.

Contact for more information:

Shoshana Keynan
VP, Head of Business Development, Healthcare
Contact ME: